Hers vs Gala: Brand-name Wegovy vs Compounded Flat-price GLP-1

Quick verdict: Hers emphasizes FDA-approved brand-name Wegovy® and ongoing dose check-ins starting from $149/mo but requires an active membership; Gala emphasizes compounded semaglutide and tirzepatide with a flat-price model and no monthly membership.

How Hers vs Gala differ at a glance

This comparison focuses on the most distinctive differences supported by the source: medication type and FDA status, pricing and membership structure, inclusion of provider visit and shipping, and care model including check-ins and monitoring. The primary keyword Hers vs Gala is covered throughout.

Medication type and regulatory status

Hers offers FDA-approved Wegovy® (brand-name semaglutide) and states it does not offer compounded medications. Gala offers compounded semaglutide and tirzepatide. The sources include the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

Pricing model and membership

Hers lists Wegovy® pill from $149/mo and injectables from $199/mo and states an active Hers Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter), with membership and medication billed separately. Gala advertises a flat-price compounded GLP-1 care, claims no monthly membership, and notes a $220 promotion but the provider base price was not exposed in readable page text.

Check Gala compounded GLP-1 pricing and $220 promotion

Care model: check-ins, provider visits, and shipping

Hers describes a personalized care team with ongoing dose check-ins. Gala includes provider visit and prescription in its direct-pay offering and advertises provider check-ins, home delivery, and free two-day shipping. Gala also markets same price at every dose and included shipping in its flat-price message.

Availability, eligibility, and state limitations

Both sources note that treatment is available only when a licensed clinician determines it is medically appropriate and that prescription and clinical eligibility apply. Hers notes medication is not available without an active membership and that services are not available in all 50 states. Gala does not list state availability details in the captured evidence.

Direct comparisons by priority

1. FDA-approved brand-name versus compounded options

Hers highlights FDA-approved Wegovy® as a brand-name semaglutide option and expressly states it does not offer compounded medications. Gala focuses on compounded semaglutide and tirzepatide and the captured evidence repeats the regulatory caveat that compounded medications are not FDA-approved.

2. Pricing transparency and membership trade-offs

Hers shows specific starting prices for Wegovy® and injectables and requires an active membership, with membership and medication billed separately and a specific renewal amount cited. Gala markets a flat-price, no-membership model and includes a $220 promotion but the base provider price was not visible in the captured page text.

3. Included services: check-ins, visits, and shipping

Both report provider check-ins and clinician review. Hers emphasizes a personalized care team with ongoing dose check-ins. Gala includes the provider visit and prescription and advertises home delivery with free two-day shipping in the captured evidence.

Final take on Hers vs Gala

Hers vs Gala comes down to a choice between FDA-approved brand-name medication with a required membership and specified starting prices, versus a compounded, flat-price model that claims no membership and includes provider visit and shipping. The primary keyword Hers vs Gala summarizes this trade-off.

Review Gala flat-price options and shipping

Choose Hers if you want FDA-approved Wegovy® (brand-name semaglutide), a personalized care team with ongoing dose check-ins, and are willing to enroll in an active membership. Choose Gala if you prefer compounded semaglutide or tirzepatide with a flat-price, no monthly membership model that includes provider visit and free two-day shipping.